ALDX (Aldeyra Therapeutics) General and Admin. Expense: $7.74 Mil (TTM As of Mar. 2026)


ALDX Aldeyra Therapeutics Inc ALDX
29 GF Score
Price $1.85
! 2 Warning Signs
View Full Analysis

What is Aldeyra Therapeutics General and Admin. Expense?

Aldeyra Therapeutics ALDX +1.95% 29 General and Admin. Expense is $7.74 Mil as of Mar. 2026. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Aldeyra Therapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was $1.14 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $7.74 Mil.

Aldeyra Therapeutics General and Admin. Expense Related Terms

Aldeyra Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics General and Admin. Expense Chart

Aldeyra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.28 15.37 13.34 11.89 9.60

Aldeyra Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 1.66 2.57 2.36 1.14
ALDX
29GF Score
Aldeyra Therapeutics Inc ALDX
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $7.74 Mil mean?
Aldeyra Therapeutics (ALDX) has a General and Admin. Expense of $7.74 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Aldeyra Therapeutics and its competitors.
Is Aldeyra Therapeutics' General and Admin. Expense too high?
Aldeyra Therapeutics' current General and Admin. Expense is $7.74 Mil. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' General and Admin. Expense compare to CGTX and RANI?
Aldeyra Therapeutics' General and Admin. Expense of $7.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Aldeyra Therapeutics and its competitors. Aldeyra Therapeutics's current General and Admin. Expense is $7.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current General and Admin. Expense of $7.74 Mil. The current General and Admin. Expense is $7.74 Mil. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current General and Admin. Expense is $7.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aldeyra Therapeutics Business Description

Other Exchanges 137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score

Get the complete analysis for ALDX

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.85
Price